Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Summary not available.
Summary not available.
Sana Biotechnology (NASDAQ: SANA) announced it will host a Research & Development (R&D) Day on May 23, 2023, in New York City from 9:00 a.m. to 12:00 p.m. ET. The event will provide a detailed overview of Sana’s R&D portfolio, specifically focusing on hypoimmune and fusogen platforms.
Key highlights include two clinical proof of concept trials expected this year: SC291, a hypoimmune-modified allogeneic CAR T product candidate targeting B-cell malignancies, and an investigator-sponsored trial utilizing hypoimmune-modified primary human islet cells for type 1 diabetes.
The event will be webcast live, with an archived replay available on Sana’s Investor Relations page.
Sana Biotechnology (NASDAQ: SANA) presented significant advancements in CAR T cell therapies at the 2023 AACR Annual Meeting. Their hypoimmune-modified CD19-directed CAR T cells demonstrated prolonged functionality, even under tumor re-challenge in preclinical models. The company revealed that SG299, a CD19 CAR T candidate, showed over 50x increased potency due to improved fusosome manufacturing. IND clearance for SC291 was achieved earlier this year, with clinical data expected shortly. Sana plans to submit INDs for SC262 and SG299 in 2023, targeting patients with hematologic malignancies. The hypoimmune platform aims to allow allogeneic cell transplants without immunosuppression, showcasing the potential for efficient CAR T cell therapies. Overall, these developments highlight Sana's commitment to transforming cancer treatment and expanding the capabilities of CAR T therapies.
Sana Biotechnology (NASDAQ: SANA) has announced promising results from preclinical studies on hypoimmune-modified CAR T cells, specifically targeting CD19. These cells demonstrated superior tumor clearance and persistence compared to unmodified CAR T cells in fully immunocompetent humanized mice. The research, published in Nature Communications, highlights the potential of these hypoimmune CAR T cells to evade immune detection, which may address current limitations in CAR T therapies. Initial clinical data for SC291 is expected later this year, with an IND submission for a second therapy, SC262, anticipated for the same timeframe. The findings underscore the transformative potential of these therapies for patients with B-cell malignancies, paving the way for future clinical applications.
Sana Biotechnology (NASDAQ: SANA) announced promising results from its hypoimmune human islet cells, which effectively normalized glucose levels in diabetic humanized mice without causing immune rejection. The study published in Science Translational Medicine reveals that these hypoimmune-modified islet cells maintained structure and function over time, avoiding any immune response. The company plans to initiate an investigator-sponsored trial in patients with type 1 diabetes later this year. Additionally, Sana aims to file an Investigational New Drug (IND) application for SC451, its hypoimmune PSC-derived pancreatic islet cell therapy, in 2024, which could significantly impact diabetes treatment.
Sana Biotechnology, Inc. (NASDAQ: SANA) has appointed Dr. Douglas E. Williams as President of Research and Development and Dr. Gary Meininger as Chief Medical Officer. These appointments are part of a planned leadership transition, with Sunil Agarwal stepping down after onboarding the new executives. Dr. Williams brings over 30 years of experience from companies like Biogen and Seattle Genetics, contributing to the development of multiple successful medicines. Dr. Meininger has extensive drug development experience, previously leading clinical development at Vertex. The new leadership aims to enhance Sana’s focus on delivering innovative gene and cell-based therapies. CEO Steve Harr expressed confidence in their ability to drive progress across the company's oncology pipeline, particularly with recent IND allowances for specific product candidates.
Sana Biotechnology reported its fourth-quarter and full-year 2022 financial results, with a cash position of $434 million as of December 31, 2022, enabling operational momentum into 2025. The recent IND clearance for SC291, a hypoimmune-modified CAR T therapy, marks a pivotal shift towards clinical-stage activities with initial data expected in 2023. The company plans to submit two additional IND applications this year, advancing a robust pipeline across multiple platforms. Despite a net loss of $269.5 million in 2022, investor confidence may be supported by strategic initiatives and anticipated clinical results.
Sana Biotechnology (NASDAQ: SANA) announced that four abstracts, including a late-breaking abstract, have been accepted for poster presentation at the 2023 AACR Annual Meeting. This meeting will take place from April 14-19, 2023, in Orlando, FL. The late-breaking abstract, titled "Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells", is set for presentation on April 19, 2023. Other significant abstracts include studies on modulation of T cell status and the development of a human anti-CD19 CAR for in vivo delivery via fusosomes.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced its participation in the Cowen 43rd Annual Health Care Conference, scheduled for March 8, 2023, at 9:50 a.m. ET. The presentation will be led by CEO Steve Harr and will provide insights into the company's business strategy and developments in engineered cell therapies. Interested parties can access the live webcast via Sana's Investor Relations page, with a replay available for 30 days post-conference. Sana aims to revolutionize disease treatment through engineered cells, with operations in key U.S. cities including Seattle and Cambridge.